Novaliq is a pharmaceutical company developing best-in-class ocular therapies based on its proprietary EyeSol® technology.
EyeSol® is the first water-free technology that opens completely new and intriguing opportunities to cure, relief and prevent diseases. Our industry-leading portfolio includes market stage and phase 3 therapies addressing unmet medical need of millions of patients with eye disorders.
In Europe and Australia NovaTears® and NovaTears®+Omega-3 are successfully commercialized as first-in-class dry eye therapies.
The next generation investigational drug products CyclASol and NOV03 have the potential to change the way eye care practitioners will treat patients with dry eye disease in the future.
Our team of industry experts is driven by the single mission: Transform ocular therapeutics to unfold the full potential of eye care treatments.
Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA.
More on www.novaliq.com